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Abstract 
Background 
Amongst the many identified mechanisms leading to diabetic foot ulceration, ill-fitting 
footwear is one. There is anecdotal evidence that people with diabetic peripheral neuropathy 
wear shoes that are too small in order to increase the sensation of fit. The aim of this study 
was to determine whether people with diabetic sensory neuropathy wear appropriate length 
footwear. 
Methods 
A case–control design was used to compare internal shoe length and foot length differences 
between a group of people with diabetes and peripheral sensory neuropathy and a group of 
people without diabetes and no peripheral sensory neuropathy. Shoe and foot length 
measurements were taken using a calibrated Internal Shoe Size Gauge® and a Brannock 
Device®, respectively. 
Results 
Data was collected from 85 participants with diabetes and 118 participants without diabetes. 
The mean difference between shoe and foot length was not significantly different between the 
two groups. However, a significant number of participants within both groups had a shoe to 
foot length difference that lay outside a previously suggested 10 to 15 mm range. From the 
diabetic and non-diabetic groups 82% (70/85) and 66% (78/118), respectively had a foot to 
shoe length difference outside this same range. 
Conclusions 
This study shows that although there is no significant difference in shoe-length fit between 
participants with and without neuropathy, a significant proportion of these populations wear 
shoes that are either too long or too short for their foot length according to the 10 to 15 mm 
value used for comparison. The study has highlighted the need for standardised approaches 
when considering the allowance required between foot and internal shoe length and for the 
measurement and comparison of foot and shoe dimensions. 
Background 
Diabetic foot ulceration is associated with increased morbidity and higher mortality rates [1-
3]. Jeffcoate and Harding [4] and Pecoraro et al [5] found that in more than 80% of cases, 
amputation was preceded by foot ulceration. The financial burden is considerable and 
Gordois et al [6] identified that foot ulcerations and amputations cost the UK National Health 
Service (NHS) £244 million in 2001. 
Boulton [7] has suggested that the lifetime risk of those with diabetes developing a foot ulcer 
is as high as 15%. There is now substantial evidence that diabetic neuropathy is a major 
aetiological factor for diabetic foot ulceration [8]. The mechanisms leading to foot ulceration 
are either extrinsic (e.g. undetected trauma) or intrinsic to the foot (e.g. neuropathy 
contributing to foot deformity resulting in high multidirectional pressures during gait) [9,10]. 
Moulik et al [11] reported the presence of neuropathy in 61% of patients presenting to a foot 
clinic for the first time with a foot ulcer. 
Other identified factors that contribute to foot ulcer risk include body weight and footwear 
[12]. Footwear has been shown to be a major contributing factor not only in the development 
of foot ulceration but also subsequent amputation [13-16]. One descriptive study reported that 
approximately half of the participants with diabetes and peripheral sensory neuropathy had a 
footwear-related event that led to limb amputation [17]. 
There is much anecdotal evidence that people with diabetic neuropathy often wear shoes that 
are too small in order to increase the sensation of fit [18]. Litzelman demonstrated that 
diabetic patients with insensate feet tend to buy and wear overly tight shoes, and at least 25% 
of people with Type 2 diabetes wear inappropriately sized footwear [15]. Published footwear 
studies of participants with diabetes use variable criteria to measure both the foot and the 
shoe and also to describe inappropriately fitting footwear [15,19-22]. There is no unified 
opinion regarding what the appropriate ‘gap’ between the distal point of the foot and the shoe 
should be in order for it to be considered an appropriate fit. This ‘gap’ seems to be arbitrary 
in length and dependent on various shoe manufacturers’ sizing systems. The work conducted 
by Chantelau and Gede [21] provides an example of this gap being 10 to 15 mm in order to 
allow "extra space for the toes when extending during walking and standing". While a 
different value has been suggested by DiMaggio and Vernon [23], their experience-based 
suggestion came after completion of the data collection phase of this study. 
The aim of this study was to determine whether people with diabetic sensory neuropathy 
wear appropriate length footwear compared with a control group. In this study Chanteleau 
and Gede's example value of 10 to 15 mm for the difference between foot and shoe length 
was used as the standard. Although Chantelau and Gede’s suggestion was not in itself 
evidence-based, it has been previously used and quoted by others, hence its use in this study. 
The hypothesis tested was: participants with diabetic peripheral neuropathy wear shorter 
footwear in relation to foot length compared to those without diabetes and peripheral 
neuropathy. This study was intended to build on the suggestions of others and provide more 
useful evidence for those involved in the care of the diabetic foot. 
Methods 
Study design 
A case–control design was implemented to compare the shoe-length fitting differences 
between two groups: (i) individuals who had both diabetes and peripheral sensory 
neuropathy, and (ii) individuals who did not have diabetes or peripheral sensory neuropathy. 
Ethical committee and research governance approval was sought and granted before the study 
commenced. All participants gave written informed consent before entering the study. The 
investigators responsible for recruitment and data collection were provided with common 
training regarding the measurement equipment used. Ethical approval was given by North 
Staffordshire Research and Ethics Committee (Reference 06/Q2604/162). 
 
Study sample and recruitment 
There is little published data concerning the relationship between foot and shoe size in people 
with diabetes and peripheral neuropathy. Harrison et al [22] considered foot length amongst 
other factors, however the measurements were all taken with participants in a standing 
position and major differences were found in relation to width measurements. In addition, it 
is not clear what, if any, allowances were made by the authors in comparing foot versus shoe 
length. It is also possible that the authors relied solely on the manufacturers (variable) stated 
length for footwear. Because of the lack of data in this area, a sample size calculation was not 
performed to ascertain the minimum number of participants required to detect clinically 
meaningful findings using statistical analysis. 
In the absence of a sample size calculation, recruitment figures were initially estimated using 
existing audit data from one of the research sites (the Leaf Hospital, Eastbourne, UK). The 
response rate for research participation by the patients at this hospital is known to be 40 to 
60%. Therefore, it was anticipated that 400 patients with diabetes would be invited to take 
part, which would translate to 160 and 240 people responding (according to the figures 
quoted above). Prior to the study commencing, it was envisaged that a similar number of 
participants for the comparison group would also be recruited. However, under recruitment 
was experienced due to time restrictions. 
Patients with diabetes who were willing to participate in the study were recruited from the 
podiatry service at the Sheffield Northern General Hospital. Approximately 70% of patients 
attending this service were ineligible for participation as they were wearing footwear 
prescribed by the hospital orthotist (see exclusion criteria below). The non-diabetic 
participants were recruited from clinics at the Leaf Hospital, Eastbourne, UK. The same 
recruitment procedures were employed at both study sites where strict adherence to protocol 
was maintained. 
Participants were eligible if they had Types 1 or 2 diabetes (with peripheral sensory 
neuropathy) or were healthy and did not have diabetes (with no sensory neuropathy) and 
between the ages of 40 and 75 years. Both males and females were included in the study. 
Exclusion criteria were: history of foot surgery; use of bespoke footwear; use of more than 
three different pairs of shoes in one week; use of dressings that may interfere with the 
measurement of the foot (e.g. an ulcer dressing on the first toe); rheumatoid arthritis, stroke, 
neurological disorders, musculoskeletal disease or major systemic arthropathy. 
All participants were asked to arrive to the clinic wearing the shoes that they most commonly 
wore outdoors.  
Assessment of peripheral neuropathy 
All participants were assessed for the presence or absence of peripheral sensory neuropathy 
of both feet by evaluating symptoms and measuring specific clinical signs using the 
neuropathic symptom score [24,25], the neuropathic disability score [26] and vibration 
perception threshold values [27]. 
The neuropathy symptom score (NSS) was used to assess the symptoms of neuropathy. An 
NSS score of greater than or equal to 3 was considered abnormal (i.e. confirmation of sensory 
neuropathy). The neuropathy disability score (NDS) was used to assess for signs of 
neuropathy. A score of 6 or above on the NDS [28] was considered abnormal. Vibration 
perception was evaluated using a 128 Hz tuning fork at three points (plantar aspect of the 
hallux, 1
st
 and 5
th
 metatarsal heads) on each foot. A 10 gram monofilament was used to test 
for pressure sensation at four points on each foot (hallux, 1
st
, 2
nd
 and 5
th
 metatarsal heads). An 
absence of the detection of pressure at one site or more indicated sensory neuropathy. A 
positive outcome for each of these tests indicated peripheral neuropathy and therefore, 
inclusion or exclusion to the study depending on whether or not the person had diabetes. 
Outcome measures 
The primary outcome measure was that of the difference between the foot and shoe length for 
both groups. The secondary outcome measure was the proportion of participants whose foot 
to shoe length difference was outside the 10 to 15 mm range. 
Foot measurements 
Both feet of each participant were measured using a Brannock Device® (Algeos, UK). Each 
participant stood barefoot and relaxed, with the feet slightly apart and with the weight evenly 
distributed between both feet. Using the Brannock Device® (Figure 1) the foot being 
measured was lifted and placed onto the base with the heel being firmly located against the 
back of the heel cup of the device with the researcher firmly holding the subject’s ankle and 
heel cup together. The researcher then pressed the subject's toes flat against the scale of the 
device, looking vertically down on the longest toe (at right angles) to note the foot length 
indicated. It is important to note that the longest toe was not necessarily the first toe. Using a 
fine, non-permanent wipe-clean marker pen and straight-edge, this position was then marked 
on the device and the distance from the heel of the device to this marked point was measured 
in millimetres (mm) using a calibrated ruler. The same procedure was repeated for the other 
foot. 
Figure 1 The Brannock
®
 device 
Footwear measurements 
The subject’s footwear was placed on a firm level surface. A calibrated Internal Shoe Size 
Gauge® (SATRA, UK) was then placed into the shoe and the flat bar of the device pushed 
into the shoe until it clearly contacted the end of the toe box (Figure 2). The slide of the 
device was then adjusted until the rear curved bar section touched the heel of the shoe. The 
internal length of the shoe was recorded in mm. The same procedure was then repeated for 
the other shoe. The measure used to test the hypothesis was the difference between the 
overall foot length and internal shoe-length. 
Figure 2 The Internal Shoe Size Gauge 
Statistical analysis 
The foot measurement was subtracted from the internal shoe length measurement and the 
difference recorded in mm. To test whether continuous data were normally distributed 
residual plots and the Shapiro–Wilk test were used. Data from the diabetes group were not 
normally distributed, so non-parametric tests were used to confirm significant differences 
between the two participant groups. For categorical variables the Chi-square test was used 
and for continuous variables that were not normally distributed the Mann–Whitney U test 
was used. It was decided a priori to use the 5% two-sided significance level to decide whether 
to reject the null hypothesis (p < 0.05). Statistical analyses were carried out using SPSS 16. 
Results 
Outcome measurements were collected for 118 control participants (i.e. without diabetes) and 
85 people with diabetes and peripheral neuropathy. A summary of descriptive data is 
provided in Table 1. The difference between internal shoe and foot size was not significantly 
different between the diabetes and control groups (p = 0.253) (Figure 3). The foot length was 
significantly greater in the group with diabetes compared to participants without diabetes 
(p = 0.001), as was the comparison between shoe-lengths (p = 0.001). 
Table 1 Shoe and foot length data for the diabetic and non-diabetic groups 
 Shoe length [mm] Foot length [mm] Shoe length minus foot length [mm] 
 Non – diabetic 
(n = 118) 
Diabetic 
(n = 85) 
Non – diabetic 
(n = 118) 
Diabetic 
(n = 85) 
Non – diabetic 
(n = 118) 
Diabetic 
(n = 85) 
Median 277 262 268 249 14 12 
Maximum 302 320 290 312 34 37 
Minimum 232 243 214 230 −5 0 
Interquartile range 21 26 30 25 14 9 
Figure 3 Comparison of the two groups and the difference in the foot and shoe lengths 
(p = 0.25) 
Seventy-eight of the 118 participants without diabetes (66%) had a difference in foot and 
shoe length outside the 10 to 15 mm range. Of those outside this range, 42 of the 78 
participants (55%) had a difference in foot to shoe length that was below 10 mm (range: -5 to 
9 mm) and 36 (47% had a difference in foot to shoe length above 15 mm (range: 16 to 34 
mm). There was a statistically significant difference in the number of participants in each 
group that were within and outside the 10 to 15 mm range (p = 0.009) (Figures 4 and 5). 
Figure 4 Comparison of the two groups and the difference in the foot lengths (p = 0.001) 
Figure 5 Comparison of the two groups and the difference in the shoe lengths (p = 0.001) 
Seventy of the 85 participants with diabetes (82%) had a difference in foot and shoe length 
outside the 10 to 15 mm range. Fifteen (18%) of these participants had a difference in foot to 
shoe length within the 10 to 15 mm range. Of those outside this range, 30 of the 70 
participants (43%) had a difference in foot to shoe length that was below 10 mm (range: 0 to 
9 mm) and 40 (57%) had a difference in foot to shoe length above 15 mm (range: 16 to 37 
mm). There was no statistically significant difference between the groups above and below 
the 10 and 15 mm range (p = 0.182). 
Discussion 
This study did not find a significant difference between the foot and internal shoe length in 
diabetic and non-diabetic subjects. A significant number of participants did, however, have a 
gap between the toe and shoe that lay outside Chantelau and Gede's [21] suggested 10 to 15 
mm range (p = 0.009). Therefore, according to Chantelau and Gede, the majority of the 
participants (72%) in our study were wearing footwear of incorrect length. In particular, 82% 
of participants with diabetes were wearing shoes of incorrect length and 35% and 36% of the 
diabetic and the non-diabetic populations respectively wore shoes that were too short. In our 
study, 47% of the diabetic population and 31% of the non-diabetic population wore shoes that 
were too long. 
Given the fitting mismatches apparent between foot and internal shoe-length, it is possible 
that participants may have developed footwear purchasing habits before being diagnosed with 
diabetes. For example, it is possible that people had their feet measured once as an adult and 
then continue to purchase the same size shoe over many years without being re-measured, 
whether or not they have been diagnosed with diabetes. It is also possible that people do not 
have their feet measured at all, basing their purchases on subjective feelings of fit adequacy 
alone; a habit that would establish the perceived fit required, and which could continue after 
receiving a diagnosis of diabetes. 
The foot and shoe length differences were significantly greater in terms of overall length in 
the diabetic group compared to the non-diabetic group. This could relate to a finding by 
Burns et al [20] who reported that some people purchase a larger shoe size than their foot in 
order to achieve a wider width fitting, with this practice resulting in a commensurate increase 
in length. In Chantelau and Gede's study [21], the foot to shoe length matched well with the 
(continental) shoe size system used, whilst the width sizes did not, which may be another 
characteristic of an ill-fitting shoe. 
Width measurements from a shoe fitting perspective should, however, involve a three-
dimensional assessment. Width measurement with a calliper or calliper-like device alone, 
such as undertaken by Chantelau and Gede [21] and Harrison et al, [22], does not take into 
consideration the depth needed to accommodate the foot – a consideration that is closely 
related to the width. As such, shoe width fitting involves a balance between the actual shoe 
width, foot width, foot depth and available shoe depth and this complexity makes the width 
dimension more difficult to measure. Therefore, width fitting may be an important factor in 
correct shoe fitting, but to achieve an acceptable width fitting, the length fitting may need to 
be compromised. 
The gap required between foot and overall internal shoe length of 10 to 15 mm as suggested 
by Chantelau and Gede is greater than others quoted in the literature (e.g. the 8.5 mm quoted 
by DiMaggio and Vernon [23]). Both values are intended to allow the foot to extend whilst 
standing and walking, however these values have also been stated within different fitting 
contexts. Continental shoe sizing systems are used across mainland Europe, where Chantelau 
and Gede are based, while US and UK shoe size systems apply to the working context of 
DiMaggio (US) and Vernon (UK). The US and UK systems half size availability of 4.25 mm 
allows a greater range of fitting choice between sizes than the Continental system, which 
allows 2/3 cm (6.66 mm) between size options [29]. As such, with fewer size options in the 
Continental system, there may be no option other than to recommend a wider allowance from 
the distal end of the toe to the shoe in order to allow adequate extension of the foot within the 
shoe. This may explain the reason for Chanteleau and Gede's larger value. 
Alternately, it is possible that Chantelau and Gede's value is erroneous. They refer to their 
10–15 mm value as an example of the gap between foot and shoe-length. However, the data 
tables presented by Chantelau and Gede appear to indicate gaps predominantly in the order of 
6–11 mm, with a modal value of 9 mm – a lower range than his suggested example and more 
in line with the 8.5 mm allowance. 
Whichever reason accounts for the differences between Chanteleau and Gede's value and 
those suggested by others, there is a need for an appropriate standardised measurement and 
sizing system. Such a system should consider all relevant factors to ensure that a baseline of 
agreement exists in relation to length and width measurements in the context of foot health. 
One inconsistency in the literature is in the measurement of foot to internal shoe-length. The 
current study used a calibrated internal shoe size gauge (mm)® (SATRA, UK), whilst others 
have used the following disparate methods, a motorised measuring apparatus [21]; a 
calibrated (in centimetres) measuring stick and conversion to shoe size [22]; nurse-clinician 
thumb size to determine end of foot to shoe gap [15]; internal calliper measurements and shoe 
size [20]; and the use of English shoe size to calibrated measuring stick [19]. 
In a previous descriptive study of one hundred participants with diabetes, the foot length was 
measured with the use of a commercial shoe company’s measuring device [22]. The foot 
length was measured both seated and standing, and the shoe length was measured in 
centimetres with the use of a calibrated stick, with differences between shoe and foot length 
being calculated and recorded. The authors concluded that about 33% of patients were more 
than a half size out in shoe length when seated. One particular finding was that there was no 
relationship between footwear size and the presence of sensory neuropathy [22]. It is not 
clear from this article what allowances were made in the study for movements such as 
slippage when comparing measurements of overall foot and internal shoe-lengths. 
The criteria for ‘ill-fitting’ footwear and the methods for measuring the foot and shoe differ 
widely. This compromises the determination of the prevalence of ill-fitting footwear in a 
diabetic population as considered in this study. Our study has attempted to determine the 
relationship of the foot length to the shoe length by taking a standardised approach to both 
foot and shoe measurements and this approach has highlighted the discrepancies and lack of 
standardisation in both the measurement techniques and allowances made in shoe fitting. 
It is important to note that loose fitting shoes can also potentially cause those pathologies that 
are related to increased levels of dynamic friction forces between the foot and shoe (e.g. 
blisters and callus formation), which in the diabetic population can have more serious 
sequelae. There is sufficient compelling evidence that footwear contributes to foot ulceration 
[14]. One study [15], investigated the role of footwear in the prevention of foot lesions in 
people with type 2 diabetes and reached a controversial conclusion that there was no 
interaction between neuropathy and footwear in the aetiology of foot wounds. However, this 
was challenged by Chantelau and Gede [21] who suggested that a significant number of 
people with diabetic neuropathy developed shoe induced foot ulcers. 
Despite the studies in this area using different methodologies and taking place within 
different operating contexts, they have reached similar conclusions; a significant number of 
people with and without diabetes do not wear appropriately sized shoes. However, the 
objective identification of specific characteristics of a good fitting shoe remains elusive. A 
trained shoe fitter can identify characteristics of a shoe that indicate poor fit, but this is very 
much a craft skill, much of which is not currently supported by research evidence. 
This study needs to be viewed in light of a few limitations. Firstly, participant characteristic 
data, such as height, age and weight, were not recorded, so we were unable to compare the 
two groups for differences in these variables. There is the possibility that some of these 
variables (e.g. height) may have had an effect on foot length. If the example of height is 
explored further, then the significant difference we found in foot length may have simply 
been due to a difference in height between the two groups. We were, however, primarily 
interested in the difference between foot length and shoe length, not foot length alone. 
Secondly, a power calculation (i.e. a sample size calculation) was not performed prior to the 
study commencing recruitment and the sample size estimate we did make was not reached. 
This may have affected whether we had sufficient statistical power to detect clinically 
worthwhile differences between shoe length and foot length. Finally, it was not anticipated 
that the majority of participants with diabetes and neuropathy would already have bespoke 
footwear, which resulted in lower numbers of eligible patients being able to enter the study. 
Further research in this area should consider a longer recruitment time and include more than 
one centre to ensure that enough participants are able to take part. 
Conclusion 
In our study we did not find a significant difference between the foot to internal shoe length 
relationship of a diabetic and non-diabetic group of adult participants. However, from a 
clinical perspective, those patients who may be considered at risk of diabetic foot 
complications can be considered to be wearing footwear that is frequently too short or too 
long. Further research is required to establish valid criteria for good-fitting footwear; 
standardise the approach to measure foot and shoe parameters of length, depth and width, and 
standardise the required gap between the foot and shoe length in order to determine ideal 
shoe-length. It is possible that certain characteristics of footwear design may interact with the 
vulnerable foot (i.e. one that has neuropathy) as opposed to characteristics that are inherently 
‘ill-fitting’. In addition to this, further work to test and validate the craft knowledge of the 
shoe fitter is pertinent. Whilst the role of the effects of therapeutic footwear has been 
evaluated [30] and the effect of footwear as a contributing factor in the pathway to diabetic 
foot ulceration has been identified [14], the lack of standardisation of footwear measurement 
prevents recording of the true prevalence of ill-fitting footwear in the diabetic population. 
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